store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
CCT251236 is an orally available Pirin ligand obtained from a heat shock transcription factor 1 (hsf1) phenotypic screen. It inhibits HSF1-mediated HSP72 induction (IC50: 19 nM).
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
2 mg | ¥ 798 | 现货 | ||
5 mg | ¥ 1,330 | 现货 | ||
25 mg | ¥ 5,690 | 6-8周 | ||
50 mg | ¥ 7,390 | 6-8周 | ||
100 mg | ¥ 11,800 | 6-8周 |
产品描述 | CCT251236 is an orally available Pirin ligand obtained from a heat shock transcription factor 1 (hsf1) phenotypic screen. It inhibits HSF1-mediated HSP72 induction (IC50: 19 nM). |
靶点活性 | SK-OV-3 cells:, HSP72:19 nM |
体外活性 | CCT367766 (0-100 nM; 24 hours) blocks 17-AAG induced he HSF1-mediated heat-shock proteins, HSP72, and HSP27 expression as a concentration manner in SK-OV-3 cells. CCT367766 blocks the induction of HSPA1A mRNA by 17-AAG in a dose-dependent manner. CCT367766 (0-100 nM; 24hours) displays the desired balance of in vitro properties while maintaining excellent cellular activity with a pIC50=7.73 ± 0.07 (IC50: 19 nM) for inhibition of HSF1-mediated HSP72 induction. The free GI50?is 1.1 nM in SK-OV-3 cells that calculated from the free fraction in the cell assay. CCT367766 (0-100 nM; 24 hours) pre-treated with 250 nM 17-AAG for 6h. |
体内活性 | CCT367766 (p.o.; 20 mg/kg; 33 days) has a clear therapeutic efficacy in mice with a tumor growth inhibition (%TGI) of 70% based on final tumor volumes. After 33 days, the mean tumor weights decrease 64% when compares to the control group. In addition, the compound's basicity and the high volume of the distribution shown in tumors with tumor concentrations of?CCT367766?as high as 940 nM. CCT367766 (p.o.; 5 or 20 mg/kg) in nontumor bearing immunocompetent BALB/c mice exhibits free?Cav0–24h?value of 2.0 nM and 1.2 nM, respectively [2]. |
分子量 | 552.62 |
分子式 | C32H32N4O5 |
CAS No. | 1693731-40-6 |
store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 150 mg/mL (271.43 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 1.8096 mL | 9.0478 mL | 18.0956 mL | 45.239 mL |
5 mM | 0.3619 mL | 1.8096 mL | 3.6191 mL | 9.0478 mL | |
10 mM | 0.181 mL | 0.9048 mL | 1.8096 mL | 4.5239 mL | |
20 mM | 0.0905 mL | 0.4524 mL | 0.9048 mL | 2.262 mL | |
50 mM | 0.0362 mL | 0.181 mL | 0.3619 mL | 0.9048 mL | |
100 mM | 0.0181 mL | 0.0905 mL | 0.181 mL | 0.4524 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
CCT251236 1693731-40-6 Cytoskeletal Signaling Metabolism HSP CCT-251236 CCT 251236 Inhibitor inhibitor inhibit